Outside of genetics, which has a well-documented link to the risk of type 1 diabetes (T1D), investigators detail available research spanning a variety of factors, including viral infections, pesticide ...
A study led by researchers from IGTP's Immunology of Diabetes group has identified new microRNA as biomarkers for the partial remission phase, also known as "honeymoon phase", of type 1 diabetes, and ...
SAB-142 shows favorable safety and pharmacodynamic activity in Phase 1 trial, advancing to Phase 2b for type 1 diabetes. SAB BIO announced positive results from its Phase 1 trial of SAB-142, a novel ...
New research (the Ver-A-T1D trial) presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) (Vienna, 15–19 September) shows that slow-release (SR) verapamil (360mg ...
Scientists uncover how exposure to a mother’s type 1 diabetes during pregnancy may epigenetically “reprogram” her child’s immune system, offering new clues to lifelong protection against the disease.
Detailed price information for Sab Biotherapeutics Inc (SABS-Q) from The Globe and Mail including charting and trades.
SAB BIO, (“SAB BIO”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results